"This development provides further validation of the efficacy of CZEN 002," said R. Steven Davidson, Ph.D., President and CEO of Zengen. "The approved patent application claims are directed to the novel peptide, which has the ability to control infection and/or inflammation associated with, among other disease states, urogenital conditions, including vaginitis."
Zengen is currently conducting Phase I/II clinical trials for CZEN 002, one of the Company's proprietary peptide molecules, for the treatment of vulvovaginal candidiasis, commonly known as vaginal yeast infection. Zengen's peptides have broad applications as anti-inflammatory and anti-infective prescription pharmaceuticals and are based on the larger melanocortin peptide, alpha-Melanocyte-Stimulating Hormone (a-MSH).
About CZEN 002
A synthetic octapeptide, CZEN 002 was developed from more than 25 years of original research in the US, Europe and Asia on peptide molecules derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). There is abundant evidence of the anti-inflammatory and anti-infective activity of CZEN 002 from both in vivo and in vitro research.
Microorganisms (e.g., fungi, bacteria, viruses) cause a host of symptoms by their occupation of vulnerable body sites, overgrowth and subsequent interference with cell metabolism, all of which give rise to a broad range of life-threatening diseases and disorders. In preclinical and clinical studies, CZEN 002 has been shown to directly kill pathologi
Contact: Kumiko Hakushi